Harry Erba, MD, PhD, professor of medicine and director, University of Alabama at Birmingham Hematologic Malignancy Program, explains the declining treatment-related mortality (TRM) rates in AML patients.
Harry Erba, MD, PhD
Advertisement
Harry P. Erba, MD, PhD, is a professor of medicine in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine at the Duke University School of Medicine, as well as director of the Leukemia Program and director of Phase I Development in Hematologic Malignancies. He is also a member of the Duke Cancer Institute
Articles by Harry Erba, MD, PhD
Dr. Harry Erba, from University of Michigan Health System, Discusses Molecular Monitoring for CML
Dr. Harry Erba, from the University of Michigan Health System, Discusses the Frontline Treatment of CML
Dr. Harry Erba, from the University of Michigan Health System, Describes Proper Diagnostic Testing of CML
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5